Belgian Drugmaker UCB Raises Full-Year Expectations on Strong US Demand

Brussels, Thursday, 22 October 2026.
UCB raised its 2026 financial guidance on October 22, 2026, projecting earnings growth in the low-to-mid 40% range due to surging U.S. sales for flagship drug Bimzelx.